Very humbly…The Regenexx-C Safety Paper is the Best of the Best! We have been dedicated to research from day 1. Way back in 2005, when we began using stem cells to treat arthritis, we did so as part of an IRB approved study. We meticulously collected data, not only on outcomes, but also on complications. This lead to two large safety papers that as of this writing, are still the largest of their kind in the world of orthopedic stem cells. The first came in 2009 when we reported on the safety of 227 patients who were treated with the Regenexx-C stem cell procedure. Our next paper was in 2011 when we reported on 339 stem cell patients. Both papers showed that the stem cell procedure was safer than common orthopedic surgery alternatives. Last year I was contacted by a research group (who I don’t know) in Europe who was compiling all the research published on the safety of advanced stem cell procedures in joints (culture expanded cells). They wanted my source data so they could perform a “systematic review” and told me they would be asking the same from a slew of other authors of similar papers. I sent them the data and frankly forgot about it. Yesterday one of the authors contacted me that their paper was just published in the prestigious medical journal Osteoarthritis and Cartilage. What did they find? They reviewed some 3,000 papers that were published on meseschymal stem cells for arthritis or for use in joints. They only accepted 8 that met their strict inclusion criteria. Ours was the only paper in that group to use a high level of sophistication when classifying complications. As a result, ours was the only one where they could use the data to compare the safety to already published papers on other common injection therapies for arthritis. In this case they compared our side effects rate for Regenexx-C to common hyaluronic acid injections (a.k.a. Rooster comb shots, knee gel shots, lubricating shots). Based on that comparison, our stem cell procedure was safer than these shots. I have to say that I was proud to see that the safety research we had published a few years ago was still the best of the best on the use of advanced stem cell therapies for arthritis. The upshot? We have a commitment to research that is almost unique among doctors who are using stem cells to treat orthopedic conditions.
RegenexxCayman is an independently owned and operated medical services provider operating exclusively in the Cayman Islands and is not part of or affiliated with the Centeno-Schultz Clinic or any U.S. Regenexx Network provider. The Regenexx-C procedure licensed by RegenexxCayman is not approved by the U.S. FDA for use in the United States.